Observe Medical ASA · OSL:OBSRV

Observe Medical ASA — Investor Presentation (June 2023)

47 slides from Observe Medical ASA's investor presentation, June 2023

  1. Slide 1: Observe Medical Company Presentation June 2023

    oYeovserve medical Observe Medical Company Presentation June 2023

  2. Slide 2: Copyright and disclaimer

    Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Observe Medical and third-party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any fo

  3. Slide 3: Management team

    Management team Rune Nystad Per Arne Nygård Carsten Bøgh Jørgen Mann Nilsen Jenny Wennerberg Chief Executive Officer Chief Financial Officer Chief Technology Officer Chief Commercial Officer QA & RA Director 20+ years of experience 20+ years of experience 20+ years experience from 20+ years experien

  4. Slide 4: Business update

    BUSINESS UPDATE

  5. Slide 5: Initial Unometer orders of NOK 8.2m received

    BUSINESS UPDATE Initial Unometer orders of NOK 8.2m received1, representing repetitive expected sales of NOK ~50m2 per year Since January 2023… After only three weeks road show… Executing according to plan: OM has received Unometer orders of NOK 8.2m ✓ Secure revenue streams and confirming orders wi

  6. Slide 6: Initial Unometer orders representing expected repetitive sales of NOK ~50m

    BUSINESS UPDATE Initial Unometer orders of NOK 8.2m received1, representing repetitive expected sales of NOK ~50m2 per year 1 Step 1: Completed (Apr/May’23) OM has targeted key Unometer NOK 200m1 distributors in Europe, accounting for 70% NOK 200m of Unometer’s yearly historical sales 25% 2 Step 2:

  7. Slide 7: Next steps

    BUSINESS UPDATE Next steps June-July 2023 August-December 2023 Q1 2024 Q2 2024 Signing and Unometer roll-out Platform Expected cash Cash positive delivery continues scale positive • Expected signing of • High momentum on • Full commercial roll- • Expected total OM2 Convatec transaction commercial ro

  8. Slide 8: Unometer distribution network secures market access and expansion

    BUSINESS UPDATE Unometer™ Unometer distribution network secures Transaction rationale and significant market access and expansion highlights Current Biim or Sippi New from Unometer Market leading products and brand Becomes Europe’s #1 urine measurement provider, supporting adoption of new products E

  9. Slide 9: Solid production partner with global reach selected

    BUSINESS UPDATE Solid production partner with global reach selected Selected solid production partner, which is expected to: ✓ Deliver production scale with high speed to facilitate a swift entry of the Unometer portfolio to large distributors globally ✓ Cost competitive to in-house production, whic

  10. Slide 10: Introduction

    INTRODUCTION

  11. Slide 11: Key investment highlights

    INTRODUCTION Key investment highlights Powerful • Observe Medical has a powerful medtech commercialization platform 1 platform • Commercializing proprietary innovative products to capitalize on significant market opportunities Commercial • The contemplated Unometer acquisition is expected to acceler

  12. Slide 12: Observe Medical is a Nordic medtech company with global reach

    INTRODUCTION Observe Medical is a Nordic medtech company with global reach Observe Medical in brief Current products and offerings • Commercializing proprietary innovative medtech Nordic distribution products on a global market • International distributor and partner network as well as Nordic direct

  13. Slide 13: Acquisition of market leading urine measurement Unometer portfolio

    INTRODUCTION Acquisition of market leading urine measurement Unometer™ portfolio to fast-track Sippi® to the market Transaction rationale and highlights Closed urine drainage system, equipped Market leading products Unometer™ with non-return valve and needleless sample and brand Safeti™ Plus port, u

  14. Slide 14: New strengthened medtech platform and extended distribution network

    INTRODUCTION The new strengthened medtech platform and extended distribution network is expected to accelerate commercialization of existing products PLATFORM • Commercializing proprietary innovative medtech products on a global market • International distributor and partner network and Nordic direc

  15. Slide 15: Reiterate run-rate revenue expectations of NOK 220m

    INTRODUCTION Reiterate run-rate revenue expectations of NOK 220m Estimated run-rate revenue of NOK 220m per Q2 20241,2 Estimated EBITDA based on a NOK 220m run-rate2 (NOK in millions) (NOK in millions) ~25 Nordic Sippi Biim Unometer Unometer Platform Gross profit OPEX EBITDA Distribution Abdo-Pressu

  16. Slide 16: Revenue, gross profit and EBITDA targets

    INTRODUCTION Revenue, gross profit and EBITDA targets Revenue development by product Gross profit and EBITDA development (NOK in millions) (NOK in millions) 800 40 265 450 600 400 60% 600 30% 300 400 0% 200 -30% 200 100 -60% - -90% - - 100 2023E 2024E 2025E 2026E -120% 2023E 2024E 2025E 2026E Unomet

  17. Slide 17: Acquisition rationale

    ACQUISITION RATIONALE

  18. Slide 18: Key acquisition highlights and rationales

    ACQUISITION RATIONALE Key acquisition highlights and rationales 1 Market leading products and brand Becomes Europe #1 urine measurement provider, supporting adoption of new products 2 Extending distribution network Access to more than 600 sales channels across 50+ countries is expected to accelerate

  19. Slide 19: Strong platform expected to strengthen sales of Sippi and Unometer

    1 ACQUISITION RATIONALE Strong platform expected to strengthen sales of both Sippi® and Unometer Targeting global market potential Accelerates rollout of Sippi® Unometer’s market position NOK 4bn Market potential Strong market position with approx. 80- The acquisition of the Unometer Market trends a

  20. Slide 20: Extending distribution network through more than 600 sales channels

    2 ACQUISITION RATIONALE Extending distribution network and market insights through more than 600 sales channels across over 50 countries Current Biim or Sippi New from Unometer • Strong distribution network enables Unometer and Sippi sales through more than 600 sales channels in 50+ new countries, a

  21. Slide 21: Expected intake of significant revenues and strong margins

    3 ACQUISITION RATIONALE Expected intake of significant revenues and strong margins with untapped potential Unometer portfolio historical revenues (NOKm) • The Unometer portfolio has previously Gross profit margin (%) 33% 30% 28% 28% had relatively low margins as Convatec has discounted the Unometer

  22. Slide 22: Sippi

    SIPPI®

  23. Slide 23: Sippi is a unique digital and automated urine meter

    Sippi® is a unique digital and automated urine meter Sippi® is the first automated digital urine meter with biofilm control and wireless connectivity, initially sold to ICUs and wards Current generation of Sippi®, with wireless connectivity to patient data monitoring systems CE-marked and with propr

  24. Slide 24: Sippi eliminates one of the last manual monitoring procedures in the ICU

    Sippi® eliminates one of the last manual monitoring procedures in the ICU Addressing key burdens of current clinical practice, A unique, automated, digital urine meter with wireless representing considerable added value and cost savings data transfer and biofilm control Burdens of current Patient we

  25. Slide 25: Significant market potential for Sippi with strong volume growth

    Significant market potential for Sippi® with strong volume growth Current global market potential Further potential for optimizing hospital implementation Current focus: ~400k ~0.5M Hospital ICU beds Sippi® base units Thoracic dept. 1 surgery 8 beds: 24M +30M BU1: 10 Hospital admitted to ICU p.a. Si

  26. Slide 26: Biim

    oeovserve medical

  27. Slide 27: Positive outlook for further Biim roll-out in Fresenius clinics

    Positive outlook for further Biim roll-out in Fresenius clinics The product Project status Ultrasound made-simple ✓ Broadly involvement of Fresenius Global An intuitive and low • Senior project manager at Fresenius to complexity device validate business case Pocketable and optimized • Regular meetin

  28. Slide 28: Biim's ultrasound probe stands out among competitors

    We believe that Biim’s unique ultrasound probe stands out among competitors Biim delivers a unique device… … which clearly stands out among its competitors Ultrasound made-simple Competitor concept disadvantages: Higher level of complexity adding An intuitive and low Wireless performance challenges

  29. Slide 29: Extensive R&D since 2014 – Fresenius agreement a major milestone

    Extensive R&D conducted since 2014 – agreement with Fresenius a major important milestone 260x Full Fresenius US rollout Phase 1 delivery Full Fresenius Completed delivery Medical Care rollout Pilot study phase 1 of 260 in the US would ultrasound probes correspond to 1.1m Pilot study involving Signe

  30. Slide 30: The dialysis market opens huge potential for Biim

    The dialysis market opens for a huge potential for Biim The market potential within dialysis is huge Fresenius partnership opens extensive growth opportunities Fresenius Medical Care is the world’s largest provider of dialysis product There are In the global market there and other services ~7,500 di

  31. Slide 31: Untapped potential to distribute Biim in adjacent market segments

    We believe there is significant untapped potential to distribute Biim in adjacent market segments Similar medical segments …where Biim has already established partnerships Dialysis Centres Vascular Access Teams ▪ A global provider of industry-leading medical devices used to treat cancer and peripher

  32. Slide 32: Key financials

    KEY FINANCIALS

  33. Slide 33: Pro forma historical revenue bridge and gross margins

    KEY FINANCIALS Pro forma historical revenue bridge and gross margins Illustrative pro forma revenue bridge FY 20211 Illustrative pro forma revenue bridge FY 20221 (NOK in millions) (NOK in millions) Observe Medical Unometer Unometer Pro forma Observe Medical Unometer Unometer Pro forma Current Abdo-

  34. Slide 34: OPEX based pro forma figures FY 2021 and FY 2022

    KEY FINANCIALS OPEX based pro forma figures FY 2021 and FY 2022 Proforma OPEX split FY 20211) Proforma OPEX split FY 2022 1) (NOK in millions) (NOK in millions) OM overhead Nordic Biim Est. OPEX Est. total OM overhead Nordic Biim Est. OPEX Est. total (incl. Sippi) Distribution new business (incl. Si

  35. Slide 35: Estimated OPEX based on NOK 220m revenue run-rate

    KEY FINANCIALS Estimated OPEX based on MNOK 220 revenue run-rate Estimated OPEX split Estimated OPEX split per cost type (NOK in millions) (NOK in millions) OM overhead Nordic Biim Est. OPEX Est. total Employee External Other Est. Total (incl. Sippi) Distribution new business expenses services OPEX

  36. Slide 36: Outlook

    OUTLOOK

  37. Slide 37: Outlook, priorities and next steps

    OUTLOOK Outlook, priorities and next steps Multiple key milestones in the short and medium term, providing a highly attractive medtech story for shareholders Sippi and Biim Unometer Outlook Ambitions Continue to support Fresenius' Regulatory: Unometer portfolio NOK 220 million in run-rate Global lea

  38. Slide 38: Appendix

    APPENDIX

  39. Slide 39: Management team

    APPENDIX Management team Rune Nystad Per Arne Nygård Carsten Bøgh Jørgen Mann Nilsen Jenny Wennerberg Chief Executive Officer Chief Financial Officer Chief Technology Officer Chief Commercial Officer QA & RA Director 20+ years of experience 20+ years of experience 20+ years experience from 20+ years

  40. Slide 40: Board of Directors

    APPENDIX Board of Directors Terje Bakken Sanna Rydberg Kathrine Gamborg Andreassen Line Tønnessen Eskild Endrerud Chairman of the Board Board Member Board Member Board Member Board Member Terje is a partner at Reiten Sanna is VD at Unilabs Kathrine is the CEO of Line is an Investment Eskild is CEO a

  41. Slide 41: Largest shareholders and company structure

    APPENDIX Largest shareholders as of 2 June 2023 Company structure Rank Name Number of shares % of top 20 % of total Country 1 INGERØ REITEN INVESTMENT COMPANY AS 9 653 680 28.95 % 18.05 % Norway Observe Medical ASA 2 NAVAMEDIC ASA 4 222 727 12.66 % 7.89 % Norway (Norway) 3 RO, LARS 3 456 789 10.37 %

  42. Slide 42: Three scientific articles support clinical value of Sippi

    APPENDIX Three scientific articles have been published Protected by IPR supporting the clinical value of Sippi® portfolio 1) A. Eklund, M. Slettengren & Jan van der Linden (2015) Performance and user evaluation of a novel ▪ The Sippi® global patent situation is capacitance-based automatic urinometer

  43. Slide 43: Consolidated Statement of Comprehensive Income

    APPENDIX Consolidated Statement of Comprehensive Income (Amounts in NOK thousand) Q1 2023 Q1 2022 FY 2022 Opera ting revenues 6 382 7 713 19 521 Cos t of ma teri a l s 3 927 4 345 14 344 Gross result 2 455 3 367 5 177 Empl oyee benefi t expens es 6 405 5 825 28 521 Other opera ting expens es 6 303 5

  44. Slide 44: Statement of financial position

    APPENDIX Statement of financial position

  45. Slide 45: Statement of financial position

    APPENDIX Statement of financial position

  46. Slide 46: Cash flow statement

    APPENDIX Cash flow statement

  47. Slide 47: oKeonserve

    oKeonserve medical

Observe Medical — Investor Presentation (June 2023) on 6ix